ESG

A Boston biotech, armed with $62M and a new name, unveils a plan to build a universal model of the cell, aiming to predict and control its behavior.

The digital-native waterproof shoe brand Vessi opens its first U.S. store, blending online savvy with a physical footprint and community support.

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

Backed by the LEGO family's firm, Adapture Renewables secures major U.S. Bank financing to build out its 441 MW Titanium solar portfolio in IL and AR.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

The MTA's major investment in Wabtec's hybrid locomotives promises cleaner air for New York, safer work for crews, and a more reliable subway system.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.

With seasoned executive Adam Rosenberg at the helm, AstronauTx is advancing its novel sleep-focused therapy, backed by major investors, into the Alzheimer's arena.

A first-in-class antibody shows a strong safety profile, de-risking development and offering a new, targeted approach for severe autoimmune diseases.

CES 2026 opens with AI dominating everything from PCs to factories, while Las Vegas reaps the rewards of a massive convention center overhaul.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

With its first drug approved and a deep pipeline, all eyes are on Nuvation Bio's CEO David Hung at the upcoming J.P. Morgan Healthcare Conference.